Regulation of osteoblastic phenotype and gene expression by hop-derived phytoestrogens.
Certain plant-derived compounds show selective estrogen receptor modulator (SERM) activity and may therefore be an alternative to the conventional hormone replacement therapy, which prevents osteoporosis but is also associated with an increased risk of breast and endometrial cancers. In the current study, we tested the effects of the hop-derived compounds 8-prenylnaringenin, 6-prenylnaringenin, xanthohumol and isoxanthohumol (1) to modulate markers of differentiation and gene expression in osteoblasts and (2) to regulate proliferation in MCF-7 breast cancer cells. Additionally, we analyzed the ER-binding affinities of these hop compounds as well as the ER-mediation of their effects. Bone-forming activity and ER-subtype specificity were investigated by measuring alkaline phosphatase (AP) activity in hFOB/ERalpha cells and regulation of gene transcription for AP, interleukin-6, pS2 and von Willebrand factor (VWF) in U-2 OS/ERalpha and U-2 OS/ERbeta cells. Our results demonstrate that AP, pS2 and VWF mRNA levels are significantly increased by the compounds in an estrogen-like manner via both ERalpha and ERbeta, while IL-6 is down-regulated in U-2 OS/ERalpha cells. Consistently, AP enzymatic activity is up-regulated by all compounds in hFOB/ERalpha9 cells. Depending on their concentration, all compounds show proliferative effects in MCF-7 cells. Except for 8-PN the hop constituents display an ERbeta-preference. Reversal of estrogen-specific AP-induction in Ishikawa cells indicates an ER-regulated mechanism. Finally, the flavonoids display cytotoxic effects only at high concentrations (> or =10(-4)M). In summary, we have demonstrated for the first time that specific phytoestrogen compounds found in hop extracts exert estrogen-like activities on bone metabolism. Regarding a potential for use in osteoporosis-prevention therapy, the dosage of a phytoestrogen, which is taken, will play an important role concerning a desired in vivo profile.
Effenberger
Katharina E
KE
Institute for Experimental and Clinical Pharmacology and Toxicology, University Hospital Eppendorf, University of Hamburg, Vogt-Koelln-Street 30, 22527 Hamburg, Germany. keffenbe@uke.uni-hamburg.de
Johnsen
Steven A
SA
Monroe
David G
DG
Spelsberg
Thomas C
TC
Westendorf
Johannes J
JJ
D000328:Adult; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy; D016466:CHO Cells; D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D006224:Cricetinae; D047628:Estrogen Receptor alpha / Q000378:metabolism; D047629:Estrogen Receptor beta / Q000378:metabolism; D004967:Estrogens / Q000378:metabolism / Q000494:pharmacology; D004997:Ethinyl Estradiol / Q000378:metabolism / Q000494:pharmacology; D005260:Female; D006801:Humans; D027582:Humulus; D010006:Osteoblasts / Q000187:drug effects*; D010024:Osteoporosis / Q000517:prevention & control; D012516:Osteosarcoma / Q000188:drug therapy; D048789:Phytoestrogens / Q000378:metabolism / Q000494:pharmacology*; D010936:Plant Extracts / Q000494:pharmacology; D015854:Up-Regulation
D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D004967:Estrogens; D048789:Phytoestrogens; D010936:Plant Extracts; D004997:Ethinyl Estradiol; D000469:Alkaline Phosphatase